Protagonist Therapeutics, Inc. $PTGX Shares Bought by Commonwealth of Pennsylvania Public School Empls Retrmt SYS

Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 11.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,913 shares of the company’s stock after acquiring an additional 1,651 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Protagonist Therapeutics were worth $880,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Envestnet Asset Management Inc. raised its holdings in shares of Protagonist Therapeutics by 85.7% during the first quarter. Envestnet Asset Management Inc. now owns 16,679 shares of the company’s stock worth $807,000 after purchasing an additional 7,698 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Protagonist Therapeutics during the 1st quarter worth about $203,000. Royce & Associates LP purchased a new position in shares of Protagonist Therapeutics during the 1st quarter valued at about $593,000. Mackenzie Financial Corp lifted its holdings in shares of Protagonist Therapeutics by 6.3% in the 1st quarter. Mackenzie Financial Corp now owns 22,698 shares of the company’s stock valued at $1,098,000 after buying an additional 1,349 shares during the period. Finally, GSA Capital Partners LLP acquired a new position in shares of Protagonist Therapeutics in the 1st quarter valued at about $579,000. 98.63% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Protagonist Therapeutics

In related news, Director William D. Waddill sold 12,000 shares of the company’s stock in a transaction dated Friday, October 10th. The shares were sold at an average price of $81.62, for a total transaction of $979,440.00. Following the completion of the transaction, the director owned 5,130 shares in the company, valued at $418,710.60. This represents a 70.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last three months, insiders have sold 20,000 shares of company stock worth $1,473,440. 4.90% of the stock is owned by corporate insiders.

Protagonist Therapeutics Price Performance

Shares of NASDAQ:PTGX opened at $85.40 on Monday. The business’s 50 day moving average price is $73.71 and its 200-day moving average price is $60.46. Protagonist Therapeutics, Inc. has a 1 year low of $33.70 and a 1 year high of $93.25. The firm has a market capitalization of $5.34 billion, a price-to-earnings ratio of 137.74 and a beta of 2.21.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.03). The company had revenue of $4.71 million during the quarter, compared to analysts’ expectations of $5.41 million. Protagonist Therapeutics had a return on equity of 6.86% and a net margin of 21.94%. On average, sell-side analysts expect that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on PTGX shares. Citigroup lifted their price target on Protagonist Therapeutics from $96.00 to $98.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Barclays raised their price objective on shares of Protagonist Therapeutics from $72.00 to $88.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Wedbush boosted their target price on shares of Protagonist Therapeutics from $70.00 to $86.00 and gave the company an “outperform” rating in a research note on Tuesday, October 28th. Leerink Partners initiated coverage on shares of Protagonist Therapeutics in a report on Friday, September 12th. They set an “outperform” rating and a $73.00 price target on the stock. Finally, BTIG Research reaffirmed a “buy” rating and issued a $82.00 price objective on shares of Protagonist Therapeutics in a report on Tuesday, October 28th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Protagonist Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $82.23.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.